Obsidian Therapeutics merges with Galera Therapeutics

Obsidian Therapeutics is set to enter the public markets through a reverse merger with Galera Therapeutics, a transaction valued at $350 million. This strategic move allows Obsidian to advance its focus on tumor-infiltrating lymphocyte (TIL) cell therapies. The merger also offers a lifeline to Galera, which had been exploring liquidation after experiencing setbacks. This merger underscores the dynamism in the biotech sector, particularly for companies focusing on next-generation cancer therapies.

The merger agreement is structured as an all-stock transaction, coupled with a $350 million private placement intended to finance the combined entity through 2028. Post-merger, the company will operate under the Obsidian Therapeutics name and apply for a listing on Nasdaq under the ticker “OBX.” Obsidian's CEO, Madan Jagasia, M.D., will lead the new entity. Galera stockholders are expected to retain around 1.8% ownership in the merged company, while existing Obsidian stockholders will own approximately 53.2%. Investors from the private placement will hold a 45% stake.

Strategically, the merger enables Obsidian to continue the development of its lead candidate, OBX-115, a genetically engineered TIL cell therapy. OBX-115 is currently in a phase 2 trial for advanced melanoma and a phase 1 trial for non-small cell lung cancer (NSCLC). The funding seeks to support these trials, with a critical milestone for the NSCLC study anticipated by 2027 and top-line results from the melanoma trial expected by year-end. OBX-115 holds fast-track and regenerative medicine advanced therapy designations from the FDA, reflecting its potential in treating patients with resistant metastatic melanoma.

For Galera, which had ceased most operations and laid off 70% of its workforce in early 2023, the merger marks a significant pivot. The company had been grappling with the failure to gain FDA approval for its drug aimed at reducing radiotherapy complications. The merger provides resources to potentially continue with research into its pan-NOS inhibitor for advanced breast cancer, thereby reviving portions of Galera's pipeline that had been dormant due to financial constraints.

The move comes amid growing interest in cell therapies targeting solid tumors, an area known for its challenges but also its potential for breakthrough treatments. Obsidian's public market entry via this reverse merger could signal increased investor interest and the potential for further consolidation in the biotech sector. Going forward, the merged entity’s success will likely depend on both advancing OBX-115 through clinical phases and effectively integrating Galera's previous research endeavors. Regulatory scrutiny will primarily focus on the company's ability to meet the projected trial timelines and deliver promised data, critical for sustaining investor confidence.